Pharmacy Medical Policy Updates
The following Pharmacy Medical Policy programs have been updated Aug. 1, 2021:
Effective Aug. 1, 2021:
- Radicava
- Otezla
- Samsca
Effective Sept. 1, 2021:
- HEMLIBRA
- Hemophilia Factor IX
- Hemophilia Factor VIII
- Human Fibrinogen Concentrate
- Selective Serotonin Inverse Agonist (SSIA)
- Topiramate ER
- Weight Loss Agents (applies to Kansas Turnpike Authority (KTA) only)
- Denosumab - Osteoporosis
- Denosumab - Oncology
- Acute Migraine Agents
- Verquvo
Many of our pharmacy medical policies are maintained through our pharmacy benefit manager, Prime Therapeutics.
To find pharmacy medical policies specific to a medication list, please select a medication list at the bottom of our prior authorization page of our website, https://www.bcbsks.com/providers/precertification-prior-authorization.
If you have any questions regarding this newsletter, please contact your BCBSKS provider representative/consultant.